JAZZ vs NBIX
JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions. NBIX: A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
Side-by-side fundamentals
| Metric | JAZZ | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $261.57 | $161.50 | |
| Market cap as of 2026-08-06 | $16.4B | $16.4B | |
| P/E as of 2026-08-06 | 570.94 | 23.62 | NBIX lower |
| PEG as of 2026-08-06 | 65.11 | 0.24 | NBIX lower |
| Net margin as of 2026-08-06 | +0.7% | +20.9% | NBIX higher |
| Gross margin as of 2026-08-06 | +88.0% | +98.0% | NBIX higher |
| Operating margin as of 2026-08-06 | -0.8% | +23.6% | NBIX higher |
| ROE as of 2026-08-06 | +0.7% | +21.1% | NBIX higher |
| ROA as of 2026-08-06 | +0.3% | +14.7% | NBIX higher |
| Debt / equity as of 2026-08-06 | 1.18 | 0.00 | NBIX lower |
| Revenue growth (YoY) as of 2026-08-06 | +9.2% | +34.4% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +5.3% | +24.3% | NBIX higher |
| Beta as of 2026-08-06 | 0.37 | 0.40 | |
| 1-year return as of 2026-08-05 close | +131.1% | +25.8% | JAZZ higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.